Safety and Effectiveness of the Akura Thrombectomy System in the Treatment of Acute Pulmonary Embolism

Exclusion Criteria

• •1. Prior PE \< 180 days from index procedure
• •2. Thrombolytic use \< 48 hours prior to baseline CTA
• •3. Pulmonary hypertension with peak pulmonary artery systolic pressure (PASP) \>70 mmHg by right heart catheterization
• •4. Vasopressor requirement after fluids to keep pressure at ≥90 mmHg
• •5. FiO2 requirement \>40% or \>6 LPM to keep oxygen saturation \>90%
• •6. Hematocrit \<28% (Note: hematocrit required within 6 hrs. of index procedure)
• •7. Platelets count \<100,000/µL
• •8. eGFR \<30 ml/min per 1.73 m2
• •9. International normalized ratio (INR) \>3
• •10. Major trauma injury severity score (ISS) \> 15
• •11. Presence of intracardiac lead in right ventricle or atrium placed within 6 months prior to screening assessment
• •12. Cardiovascular or pulmonary surgery within 7 days of index procedure
• •13. Actively progressing cancer treated by chemotherapeutics
• •14. Known bleeding diathesis or coagulation disorder
• •15. Left bundle branch block
• •16. History of severe or chronic pulmonary arterial hypertension
• •17. History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
• •18. History of decompensated heart failure
• •19. History of underlying lung disease that is oxygen dependent
• •20. History of chest irradiation
• •21. History of heparin-induced thrombocytopenia (HIT)
• •22. Contraindication to systemic or therapeutic doses of anticoagulants
• •23. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
• •24. Known residual iliac deep vein thrombosis (DVT), inferior vena cava (IVC) clot or clot in transit (right atrium and/or right ventricle).
• •25. CTA imaging or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for aspiration thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
• •26. Life expectancy \<90 days, as determined by investigator
• •27. Female who is pregnant or nursing
• •28. Current participation in another investigational drug or device treatment study Note: observational or registry studies may be permitted with Sponsor approval